New publication “Our immune system: guardian, mediator, and betrayer”

Our immune system protects us from pathogens and fights cancer. It consists of a whole army of immune cells and antibodies. When the immune system fails or reacts unnecessarily or excessively, it results in immune disorder, allergies, or autoimmune diseases. Fortunately, there are a growing number of insights into how these ‘mistakes’ in our immune system emerge.

In the new publication, people tell their stories about the impact of their disease on their lives. After these stories, immunologists, pulmonologists, paediatricians, allergists, dermatologists, neurologists, haematologists, oncologists, cell biologists, microbiologists, and epidemiologists tell the story from their perspective and profession. They also explain how the immune system is involved, what the current treatments are and what new treatments are expected in the future.

This publication is the result of a cooperation between scientists and specialists from, among others UMCU, UMCG, LUMC, Radboudumc, VUmc, AMC UvA, Erasmus MC, RIVM, Sanquin Research, University College Roosevelt, and Wageningen University & Research.

Interested? Read the publication (in Dutch) here. Or read how the Top Sector LSH stimulates new research on the immune system.

Trend analysis: Great year for Dutch biotech R&D 

For the Dutch biotech research and development efforts, 2017 proved to be remarkably fruitful. The development pipeline contains more products than previous years. Currently, 42 phase I, 47 phase II and 11 phase III studies are registered, which is almost twice as much as the total number of studies reported two years ago. And the preclinical studies are impressive, too. In total, 97 products are in preclinical development, holding promise for a bright future.

The total number of biotech companies is relatively stable: 455. The analysis reflects a well-established Dutch biotech sector. The data confirms the status of The Netherlands as Europe’s most attractive and innovative biopharmaceutical industry environment.

According to HollandBIO’s managing director Annemiek Verkamman, the Dutch Life Sciences sector is rewarding like no other. ‘In terms of scientific excellence and technological innovation the Netherlands is on top of Europe’s list. In our joint vision Life Sciences 2030, we show that our sector has what it takes to evolve into one of world’s leading clusters in 2030. The data of the trend analysis show we are on the right track!’

Download full report.

Biotechgate is a global business development database containing over 50,000 high-quality company profiles including company descriptions, contact information, product pipeline information, financing rounds and more. Biotechgate is owned and operated by Venture Valuation AG, a Zurich-based company specializing in independent assessment and valuation of technology-driven companies in high-growth industries.

Whether you are looking to partner with a Dutch company or looking for a specific service, you’ll find the most complete overview of the Dutch life sciences sector at

Source: HollandBIO

Introducing new Advisory Board member André van de Sande

In April 2018, André van de Sande joined the Advisory Board of the Top Sector Life Sciences & Health (LSH). He has 30 years of Life Sciences experience as a senior executive in both mature and emerging markets in Western and Central Europe, Asia Pacific and Middle East Africa. On 1 February 2011, André van de Sande became the CEO of Xendo. He is also a former Chairman of the Dutch Biotech Association BioFarmind where he worked on the merger with Niaba to form HollandBio. Within the Advisory Board of the Top Sector LSH, André van de Sande represents the industry. So who is André van de Sande and what is his vision for the sector?

Patients, doctors, scientists and financiers join forces in Dutch CardioVascular Alliance

Ambition: detecting cardiovascular diseases at an earlier stage, developing solutions faster and offering these to patients quicker. 

Suddenly experiencing an infarct or stroke will be a thing of the past within 10 years. That is the ambition of the Dutch Cardiovascular Alliance (DCVA), a new collaboration between twelve organisations, involving scientists, Top Sector Life Sciences & Health and healthcare professionals in the area of cardiovascular research. The DCVA was festively launched today during a presentation in the Muntgebouw in Utrecht.

Within NeurolabNL researchers, knowlegde institutes and societal partners work together to implement knowledge about the brain, cognition and behaviour in daily life of people. This partnership studies over 400 brain-related questions that came up via the National Research Agenda process last year. Questions like: ‘how is it possible that some children develop more rapid than others?’ and ‘which innovative treatments can be developed for psychical and physical disorders, other than classical pharmacology?’

Download the digital agenda here.

The realisation of the NeuroLabNL agenda has been captured in the following movie: